Nordic Cell Therapy Group: Expertise Across Cell Therapy Development

Developing a cell therapy requires much more than generating the right cell.

From early development strategy and manufacturing to analytical characterization, potency, cryopreservation, non-clinical development and regulatory planning, translating promising biology into a viable therapeutic product requires expertise across many interconnected disciplines.

Nordic Cell Therapy Group (NCTG) was created to bring that expertise together.

Based in Copenhagen, NCTG is a specialized cell therapy company supporting biotechnology companies, academic groups and other developers as they move cell-based therapies from research toward clinical development.

Specialized consulting for cell therapy developers

NCTG's consulting activities focus exclusively on cell therapy.

The team supports programs across areas including CMC and process development, analytical and potency strategy, formulation and cryopreservation, raw materials, non-clinical development, regulatory strategy, device and delivery considerations, and translational development.

Rather than providing generic biotechnology consulting, NCTG works directly with the scientific and development questions that arise when turning living cells into therapeutic products.

Advanced cell analytics

NCTG also develops and performs specialized analytical solutions for cell therapy programs.

Its Analytics activities combine technologies including flow cytometry, molecular and genomic approaches, cell-based assays and data analysis to help developers better characterize their cells, understand process performance and build analytical strategies appropriate for increasingly mature therapeutic programs.

This combination of laboratory capabilities and development expertise allows analytical work to be considered in the context of the therapeutic product — not simply as an isolated assay.

Expertise that can also create new therapies

The same capabilities used to support other cell therapy developers can also provide the foundation for new therapeutic programs.

Corcellys Therapeutics emerged from this environment.

Building on ophthalmology experience and cell therapy development capabilities within NCTG, Corcellys was established as a dedicated biotechnology company focused on regenerative therapies for the ocular surface.

It represents one example of how expertise developed across cell therapy consulting, analytics and therapeutic development can come together around a specific unmet medical need.